HanAll to complete Phase II study for Hanferon in U.S. by next February

HanAll BioPharma plans to complete Phase II clinical trial for its biosimilar product Hanferon (interferon alpha; HL-143) in the U.S. during February 2012, as the drug has been successfully administered to all patients in six U.S. hospitals since its first dosing on July 6.

Biosimilars, or imitation biopharmaceuticals, are officially approved subsequent versions of innovative biopharmaceutic...